Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.

ABSTRACT:

Study objective

Alemtuzumab is a monoclonal antibody that targets the cell surface antigen CD52 on lymphocytes. Although it is used for the treatment of hematologic malignancies, such as chronic lymphocytic leukemia, and incorporated into many hematopoietic stem cell transplant (HSCT) conditioning regimens, few studies have evaluated the pharmacology of alemtuzumab in adult patients with sickle cell disease (SCD). We therefore examined the pharmacokinetics (PK) and pharmacodynamics (PD) of alemtuzumab in adults with SCD who received a matched related donor HSCT to determine if the clearance of alemtuzumab affects transplant outcomes.

Design

PK and PD analysis of patient data from a single-center clinical trial.

Setting

Clinical research center.

Patients

Twenty-

SUBMITTER: Furstenau D 

PROVIDER: S-EPMC9338787 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature